Ultragenyx Pharma (RARE) Tops Q3 EPS by 33c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.08), $0.33 better than the analyst estimate of ($1.41). Revenue for the quarter came in at $81.6 million versus the consensus estimate of $81.55 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tactical Resources Completes Business Combination with Plum Acquisition Corp. III and Prepares for Nasdaq Listing
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c